Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Funko, Bloomin' Brands, Johnson & Johnson, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Funko, Bloomin' Brands, Johnson & Johnson, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
Vaccine Stocks Down as Omicron May Not Be Too Severe
by Kinjel Shah
Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.
J&J (JNJ) COVID-19 Booster Jab Compares Well With Comirnaty
by Zacks Equity Research
Booster dose of J&J's (JNJ) COVID-19 vaccine elicits comparable neutralizing activity and higher T-cell responses in previously-vaccinated persons with Comirnaty.
AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label
by Zacks Equity Research
AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron
COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron
by Kinjel Shah
The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.
Pfizer (PFE) Up 22% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review
by Zacks Equity Research
Merck (MRK) is seeking label expansion for Vaxneuvance for use in pediatric patients aged six weeks through 17 years for the prevention of invasive pneumococcal disease. A decision is expected by on Apr 1, 2022.
Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote
by Zacks Equity Research
An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.
Moderna's (MRNA) Stock Falls on Omicron Variant Concerns
by Zacks Equity Research
Moderna (MRNA) shares decline following a two-day rise as the Omicron-variant creates uncertainty with limited data. The next couple of weeks may provide a clearer picture.
The Zacks Analyst Blog Highlights: Mastercard, Pfizer, Nike, Lockheed Martin and Micron Tech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Pfizer, Nike, Lockheed Martin and Micron Tech
Top Research Reports for Mastercard, Pfizer & Nike
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Pfizer Inc. (PFE), and NIKE, Inc. (NKE).
Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas
by Zacks Equity Research
Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.
Moderna (MRNA) Rallies on Booster Hopes Amid Omicron Concerns
by Zacks Equity Research
Demand for Moderna's (MRNA) COVID-19 vaccine booster dose might increase if the Omicron variant causes a rise in infection rates.
J&J (JNJ) to Explore Omicron Version of its COVID Vaccine
by Zacks Equity Research
J&J (JNJ) is testing the blood serum from participants of completed and ongoing booster studies for neutralizing activity against the Omicron variant
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax
Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?
by Zacks Equity Research
Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.
ETF Areas to Gain/Lose on Fear of Omicron Strain of Coronavirus
by Sanghamitra Saha
The emergence of a new coronavirus strain, namely Omicron, has caused a massacre on Wall Street on Friday. These ETFs could gain/lose in the coming days if Omicron cases continue to rise.
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Cyber Monday to Determine Holiday Sales Fate
by Zacks Equity Research
Cyber Monday to Determine Holiday Sales Fate
Will Cyber Monday Rescue Holiday Shopping from Omicron Fears?
by Mark Vickery
Pre-market futures this morning are buoyant, indicating market participants may have overreacted to the Friday news.
Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down
by Zacks Equity Research
Merck's (MRK) new data from a phase III study shows its COVID-19 antiviral pill is less effective than previously reported.
4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio
by Zacks Equity Research
Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.
Wall Street Tumbles on Resurgence of Coronavirus
by Zacks Equity Research
Wall Street Tumbles on Resurgence of Coronavirus.
Black Friday Meets "Black Friday:" New Covid Variant Hits Markets
by Mark Vickery
A new Covid strain threatens the global marketplace anew, just as economic conditions around the world were beginning to get their footing following the Delta-variant fallout.